Xvivo Perfusion AB 2024 AR2
The report highlights XVIVO's strong financial and operational performance in 2024, achieving net sales of SEK 822 million with 39% organic growth. Key milestones included the first-ever transatlantic transport of a donor heart using XVIVO's heart technology and the acquisition of FlowHawk, a digital communication platform for transplantation. The company also completed patient enrollment five months early in its US clinical trial evaluating heart preservation technology. In sustainability, XVIVO conducted its first greenhouse gas emissions inventory under the GHG Protocol and completed a double materiality assessment in preparation for CSRD alignment.
Company: Xvivo Perfusion AB
Sector: Health Care
Country: Sweden
Year: 2024
Type: AR2
Pages: 119
Xvivo Perfusion AB
Annual Report
The report highlights XVIVO's strong financial and operational performance in 2024, achieving net sales of SEK 822 million with 39% organic growth. Key milestones included the first-ever transatlantic transport of a donor heart using XVIVO's heart technology and the acquisition of FlowHawk, a digital communication platform for transplantation. The company also completed patient enrollment five months early in its US clinical trial evaluating heart preservation technology. In sustainability, XVIVO conducted its first greenhouse gas emissions inventory under the GHG Protocol and completed a double materiality assessment in preparation for CSRD alignment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Employees